Volume 15, Number 2—February 2009
Meningitis Caused by Streptococcus suis Serotype 14, North America
To the Editor: Streptococcus suis is an opportunistic pathogen that can cause serious systemic infections in pigs and occupation-related infections in humans who work in close contact with pigs or pork by-products. Most S. suis organisms isolated from diseased pigs belong to serotypes 1–8 (1). The most prevalent strain worldwide is serotype 2, which causes invasive infections in pigs and humans (2). We report a case of human meningitis caused by S. suis serotype 14.
The patient was a 59-year-old woman from rural Manitoba, Canada; she worked at a hog plant and handled 300–400 piglets/day. In October 2007, when she sought care, she had a 2-day history of fever, vomiting, headache, neck pain, and reduced consciousness. She was febrile and confused and had meningeal signs. Leukocyte count was 19,900/mm3. Cerebrospinal fluid (CSF) had 284 × 106/L leukocytes (59% lymphocytes, 41% polymorphonuclear cells), 2.3 mmol/L glucose, and 1.85 g/L total protein. Gram stain of CSF showed gram-positive cocci in pairs; cefotaxime and vancomycin were prescribed empirically. Results of computed tomography of the head, chest radiograph, and transesophageal echocardiogram were within normal limits. Blood culture was negative after 5 days of incubation. The CSF culture grew small α-hemolytic colonies on blood agar and chocolate agar. The organisms were gram-positive cocci in chains, were catalase negative, and were identified as S. suis by Vitek II and API 20 Strep System (both from bioMérieux, St.-Laurent, Quebec City, Canada).
Identification of the organism as S. suis was confirmed at the National Microbiology Laboratory, Winnipeg, Manitoba, Canada, by conventional biochemical tests (3), the results of which were consistent with that of the type strain (Table) and were also confirmed by 16S rRNA gene sequencing, which showed 100% homology with the S. suis type strain ATCC 43765, GenBank accession no. EU 477176.
Antimicrobial-drug susceptibilities were determined by microbroth dilution by using Sensititre STP3F panels (Nova Century Scientific Inc., Burlington, Ontario, Canada) and cation-adjusted Mueller Hinton broth with lysed horse blood (2%–5% vol/vol) by TREK Diagnostic Systems, Inc. (Nova Century Scientific Inc.) using manufacturer's instructions and following Clinical and Laboratory Standards Institute guidelines for Streptococcus spp. other than S. pneumoniae (4). This isolate was sensitive to penicillin, cefepime, cefotaxime, ceftriaxone, linezolid, trimethoprim and sulfamethoxazole, vancomycin, meropenem, and levofloxacin; it was resistant to azithromycin, erythromycin, and tetracycline. The isolate was sent to the International Reference Laboratory at the Université de Montréal, Montréal, Québec, Canada, for S. suis serotyping, where it was identified by the coagglutination test as serotype 14 (5).
The patient recovered quickly, and her therapy was changed to penicillin G. She was transferred to her local hospital to complete her medication. Within a week of her initial visit, bilateral deafness and loss of balance developed and progressed over the next month and had not ameliorated after 1 year.
Human S. suis infections result primarily from direct contact (with wounds on skin or mucosa of the mouth and nasal cavity) with carrier pigs, sick pigs, or raw pork contaminated with S. suis (2). The infection rate among abattoir workers, pig breeders, meat processing workers, and veterinarians is ≈3 cases/100,000 (1,500× higher than the rate for the general population) (2). A striking sequela to S. suis meningitis is deafness or vestibular dysfunction (2,6). A consistently higher percentage of persons experiences deafness after S. suis infection than after infection with other meningitis-causing bacteria, 50% and 65% in Europe and Asia, respectively (2).
Most cases of S. suis infection in humans have been attributed to serotype 2 strains. Only 4 human cases have been reported in North America: 2 in Canada (1 endocarditis, 1 meningitis) and 2 cases of meningitis in the United States (6–9). All 4 cases were attributed to S. suis serotype 2. Serotype 14 has been reported as a human pathogen in the Netherlands, Thailand, the United Kingdom, and Denmark and has been routinely isolated from diseased pigs in Canada (10).
Although in pigs the organism is present in the upper respiratory tract, particularly the tonsils, nasal cavities, genital tract, and alimentary tract, the mode of transmission to humans reported so far had been through cuts in the hands. Our patient handled hundreds of piglets every day and most likely acquired the infection through her hands. Her meningitis was complicated by bilateral hearing loss with vestibular dysfunction. Preexisting medical conditions, such as alcoholism, liver cirrhosis, or splenectomy, have been described to predispose patients to severe infection and hearing loss (2). Our patient, however, did not have any predisposing conditions.
Meningitis in humans caused by S. suis serotype 14 is less common than that caused by serotype 2, but the consequences are similar and can be reduced by early treatment with antimicrobial drugs. Identifying this case of meningitis caused by S. suis serotype 14 in Canada raises concerns about the public health aspect of this infection. Guidelines may be required to ensure that staff working in hog plants are aware of the risk for this infection and that they use adequate personal protective equipment.
- Higgins R, Gottschalk M. Streptococcal diseases. In: Straw BE, D’Allaire S, Mengeling WL, Taylor DJ, editors. Diseases of swine. Ames (IA): Iowa State University; 2005. p. 769–83.
- Gottschalk M, Segura M, Xu J. Streptococcus suis infections in humans: the Chinese experience and situation in North America. Anim Health Res Rev. 2007;8:29–45.
- Kilpper-Balz R, Schleifer KH. Streptococcus suis sp. nov., nom. rev. Int J Syst Bacteriol. 1987;37:160–2.
- Clinical and Laboratory Standards Institute. Performance for antimicrobial susceptibility testing; Eighteenth informational supplement. CLSI document M100-S18. Wayne (PA): The Institute; 2008.
- Gottschalk M, Higgins R, Boudreau M. Use of polyvalent coagglutination reagents for serotyping of Streptococcus suis. J Clin Microbiol. 1993;31:2192–4.
- Lee GT, Chiu CY, Haller BL, Denn PM, Hall CS, Gerberding JL. Streptococcus suis meningitis, United States. Emerg Infect Dis. 2008;14:183–5.
- Trottier S, Higgins R, Brochu G, Gottschalk M. A case of human endocarditits due to Streptococcus suis in North America. Rev Infect Dis. 1991;13:1251–2.
- Michaud S, Duperval R, Higgins R. Streptococcus suis meningitis: first case reported in Quebec. Can J Infect Dis. 1996;7:329–31 [cited 2009 Jan 12]. Available from http://www.pulsus.com/journals/journalHome.jsp?HCtype=Physician&jnlKy=3&/home.htm&
- Willenburg KS, Sentochik DE, Zadoks RN. Human Streptococcus suis meningitis in the United States. N Engl J Med. 2006;354:1325.
- Messier S, Lacouture S, Gottschalk M. Groupe de Recherche sur les Maladies Infectieuses du Porc (GREMIP); Centre de Recherche en Infectiologie Porcine (CRIP). Distribution of Streptococcus suis capsular types from 2001 to 2007. Can Vet J. 2008;49:461–2.
- Table. Identification of organism isolated from cerebrospinal fluid of 59-year-old woman with meningitis, Manitoba, Canada
Suggested citation for this article: Haleis A, Alfa M, Gottschalk M, Bernard K, Ronald A, Manickam K. Meningitis caused by Streptococcus suis serotype 14, North America [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Feb [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/2/08-0842
Please use the form below to submit correspondence to the authors or contact them at the following address:
Kanchana Manickam, St. Boniface General Hospital, Clinical Microbiology, 409 Tache Ave, Winnipeg, Manitoba R2H 2A6, Canada
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 08, 2010
- Page last updated: December 08, 2010
- Page last reviewed: December 08, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)